Optimised adenovirus engineering, production cell lines and proprietary TERA system.
Design and optimise
We design, assemble and produce adenoviral vectors tailored to your application.
Our process development experts support you to expedite on-boarding of technologies and to facilitate technology transfer to your laboratories or to a partner CMO.
License for manufacture
We provide a HEK293 and HEK293TetR suspension cell line to facilitate industry-leading performance in adenoviral manufacture.
OXGENE can design, assemble and produce adenoviral vectors of any genetic composition to facilitate both gene therapy and oncolytic applications.
Adenovirus at the edge of impossible
OXGENE has developed a bespoke, GMP-compliant, suspension HEK293TetR cell line for amplification of cytotoxic adenoviral vectors. This animal component and antibiotic free system shows improved viral titre when benchmarked against industry-standard alternatives and allows optimisation of adenoviral production even for transgenes that reduce cell viability. Our vector systems are also available for licensing, so gene therapy developers can proceed without freedom-to-operate or traceability/regulatory concerns, and simultaneously reduce their therapeutic cost of goods.
OXGENE has engineered the adenoviral genome to allow temporal control and separation of the adenoviral life cycle. This enables adenoviral helper function during AAV manufacture while completely removing adenoviral particle contamination.
We have built a switchable negative feedback loop into the viral genome to prevent structural gene expression. This system, called ‘Tetracycline-Enabled Repressible Adenovirus’ (TERA), allows normal adenovirus replication in the presence of doxycycline, but represses viral particle production in its absence.
The system has been validated through transient AAV5 production, and is available for early-access evaluation, as well being further developed to complement our in-house stable cell line solutions.
OXGENE is also conducting early-access and collaborative projects to explore further applications of the TERA system. Please email firstname.lastname@example.org to find out more.
HEK293TetR Cell Line
OXGENE has successfully developed a GMP-compliant suspension HEK293TetR cell line for amplification of cytotoxic adenoviral vectors.
We have demonstrated the functionality of this cell line through our partnership with Vaccitech, and through partner CMOs. In all cases this outperformed commercial alternatives and demonstrates improved scalability and full stability in the absence of antibiotics.